This trial is comparing two dosing regimens of oral edaravone to see which is more effective in treating ALS. The primary outcome measure is time from randomization to either a 12-point decrease in ALSFRS-R score or death, whichever happens first.
1 Primary · 8 Secondary · Reporting Duration: Up to 96 weeks
300 Total Participants · 2 Treatment Groups
Primary Treatment: MT-1186 · Has Placebo Group · Phase 3
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Nerve And Muscle Center Of Texas||100.0%|
|Did not meet criteria||100.0%|